Physician profile
Mark A Stern
NPI 1033201579
$5,689.33
in general payments reported to CMS, 2019-2025
20 companies · $79.64 in 2025
The $79.64 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,182 · 2020: $1,105 · 2021: $1,330 · 2022: $1,500 · 2023: $247 · 2024: $247 · 2025: $79.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $573.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $572.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,484.85 | 2019-2024 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $807.84 | 2019-2025 | |
| Abbvie INC. | $771.90 | 2019-2022 | |
| Medtronic, INC. | $477.62 | 2022 | |
| Genentech USA, INC. | $395.03 | 2019-2020 | |
| Ucb, INC. | $336.91 | 2020-2025 | Bimzelx |
| Lilly USA, LLC | $311.75 | 2019-2022 | |
| Horizon Therapeutics Plc | $263.52 | 2020-2023 | Krystexxa |
| Pfizer INC. | $189.27 | 2020-2022 | |
| Celgene Corporation | $156.74 | 2019 | |
| Janssen Biotech, INC. | $102.65 | 2021-2022 | |
| Osteomed LLC | $69.42 | 2019-2021 | |
| Genzyme Corporation | $66.95 | 2019-2020 | |
| Bioventus LLC | $66.29 | 2019-2021 | |
| Daiichi Sankyo INC. | $57.76 | 2019-2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $56.10 | 2020-2021 | |
| Astrazeneca Pharmaceuticals Lp | $24.97 | 2022 | |
| Aurinia Pharma U.S., INC. | $19.24 | 2021 | |
| Alexion Pharmaceuticals, INC. | $18.67 | 2022 | |
| Sanofi-Aventis U.S. LLC | $11.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Stern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.